Patents by Inventor Peter A. Lando
Peter A. Lando has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8548594Abstract: According to one aspect, a stimulation system is provided for electrically stimulating a predetermined site to treat a neurological condition. The system includes an electrical stimulation lead adapted for implantation into a subcutaneous area in communication with a predetermined site, wherein the site is neuronal tissue that is associated with C2/C3 dermatome area, or stimulating cervical nerve roots and/or stimulating cranial nerves and/or stimulating any area associated with the occipital area. The stimulation lead includes one or more stimulation electrodes adapted to be positioned in the predetermined site. The system also includes a stimulation source that generates the stimulation pulses for transmission to the one or more stimulation electrodes of the stimulation lead to deliver the stimulation pulses to the predetermined site to treat a neurological disorder or condition.Type: GrantFiled: February 28, 2012Date of Patent: October 1, 2013Assignee: Advanced Neuromodulation Systems, Inc.Inventors: Mark Thimineur, Ed Kravitz, Peter Lando, Tracy Cameron, Rohan Hoare
-
Patent number: 8340771Abstract: According to one aspect, a method of treating a patient by electrically stimulating a predetermined site to treat a neurological condition. The method includes implanting a lead into subcutaneous tissue of the C2 dermatome/C3 dermatome area.Type: GrantFiled: April 19, 2010Date of Patent: December 25, 2012Assignee: Advanced Neuromodulation Systems, Inc.Inventors: Mark Thimineur, Ed Kravitz, Peter Lando, Tracy Cameron, Rohan Hoare
-
Publication number: 20120158092Abstract: According to one aspect, a stimulation system is provided for electrically stimulating a predetermined site to treat a neurological condition. The system includes an electrical stimulation lead adapted for implantation into a subcutaneous area in communication with a predetermined site, wherein the site is neuronal tissue that is associated with C2/C3 dermatome area, or stimulating cervical nerve roots and/or stimulating cranial nerves and/or stimulating any area associated with the occipital area. The stimulation lead includes one or more stimulation electrodes adapted to be positioned in the predetermined site. The system also includes a stimulation source that generates the stimulation pulses for transmission to the one or more stimulation electrodes of the stimulation lead to deliver the stimulation pulses to the predetermined site to treat a neurological disorder or condition.Type: ApplicationFiled: February 28, 2012Publication date: June 21, 2012Applicant: ADVANCED NEUROMODULATION SYSTEMS, INC.Inventors: Mark Thimineur, Ed Kravitz, Peter Lando, Tracy Cameron, Rohan Hoare
-
Publication number: 20110098778Abstract: According to one aspect, a method of treating a patient by electrically stimulating a predetermined site to treat a neurological condition. The method includes implanting a lead into subcutaneous tissue of the C2 dermatome/C3 dermatome area.Type: ApplicationFiled: April 19, 2010Publication date: April 28, 2011Applicant: ADVANCED NEUROMODULATION SYSTEMS, INC.Inventors: Mark Thimineur, Ed Kravitz, Peter Lando, Tracy Cameron, Rohan Hoare
-
Publication number: 20100204749Abstract: According to one aspect, a stimulation system is provided for electrically stimulating a predetermined site to treat a neurological condition. The system includes an electrical stimulation lead adapted for implantation into a subcutaneous area in communication with a predetermined site, wherein the site is neuronal tissue that is associated with C2/C3 dermatome area, or stimulating cervical nerve roots and/or stimulating cranial nerves and/or stimulating any area associated with the occipital area. The stimulation lead includes one or more stimulation electrodes adapted to be positioned in the predetermined site. The system also includes a stimulation source that generates the stimulation pulses for transmission to the one or more stimulation electrodes of the stimulation lead to deliver the stimulation pulses to the predetermined site to treat a neurological disorder or condition.Type: ApplicationFiled: April 19, 2010Publication date: August 12, 2010Applicant: ADVANCED NEUROMODULATION SYSTEMS, INC.Inventors: Mark Thimineur, Ed Kravitz, Peter Lando, Tracy Cameron, Rohan Hoare
-
Patent number: 7711432Abstract: According to one aspect, a stimulation system is provided for electrically stimulating a predetermined site to treat a neurological condition. The system includes an electrical stimulation lead adapted for implantation into a subcutaneous area in communication with a predetermined site, wherein the site is neuronal tissue that is associated with C2/C3 dermatome area, or stimulating cervical nerve roots and/or stimulating cranial nerves and/or stimulating any area associated with the occipital area. The stimulation lead includes one or more stimulation electrodes adapted to be positioned in the predetermined site. The system also includes a stimulation source that generates the stimulation pulses for transmission to the one or more stimulation electrodes of the stimulation lead to deliver the stimulation pulses to the predetermined site to treat a neurological disorder or condition.Type: GrantFiled: July 26, 2005Date of Patent: May 4, 2010Assignee: Advanced Neuromodulation Systems, Inc.Inventors: Mark Thimineur, Ed Kravitz, Peter Lando, Tracy Cameron, Rohan Hoare
-
Publication number: 20060047325Abstract: According to one aspect, a stimulation system is provided for electrically stimulating a predetermined site to treat a neurological condition. The system includes an electrical stimulation lead adapted for implantation into a subcutaneous area in communication with a predetermined site, wherein the site is neuronal tissue that is associated with C2/C3 dermatome area, or stimulating cervical nerve roots and/or stimulating cranial nerves and/or stimulating any area associated with the occipital area. The stimulation lead includes one or more stimulation electrodes adapted to be positioned in the predetermined site. The system also includes a stimulation source that generates the stimulation pulses for transmission to the one or more stimulation electrodes of the stimulation lead to deliver the stimulation pulses to the predetermined site to treat a neurological disorder or condition.Type: ApplicationFiled: July 26, 2005Publication date: March 2, 2006Inventors: Mark Thimineur, Ed Kravitz, Peter Lando, Tracy Cameron, Rohan Hoare
-
Patent number: 6962694Abstract: A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in that at least one of the superantigen and the immune modulator is in the form of a conjugate between a “free” superantigen (Sag) and a moiety targeting the conjugate to the target cells. A superantigen conjugate complying with the formula (1) (T)x(Sag)y(IM)z; a) T is a targeting moiety, Sag corresponds to a free superantigen, IM is an immune modulator that is not a superantigen and T, Sag and IM are linked together via organic linkers B; b) x, y and z are integers that typically are selected among 0-10 and represent the number of moieties T, Sag and IM, respectively, in a given conjugate molecule, with the provision that y>0 and also one or both of x and z>0. The superantigen conjugate is preferably a triple fusion protein.Type: GrantFiled: July 21, 1998Date of Patent: November 8, 2005Assignee: Active Biotech AGInventors: Morten Soegaard, Lars Abrahmsen, Peter Lando, Goran Forsberg, Terje Kalland, Mikael Dohlsten
-
Publication number: 20050226885Abstract: A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in that at least one of the superantigen and the immune modulator is in the form of a conjugate between a “free” superantigen (Sag) and a moiety targeting the conjugate to the target cells. A superantigen conjugate complying with the formula (1): (T)x(Sag)y(IM)z; a) T is a targeting moiety, Sag corresponds to a free superantigen, IM is an immune modulator that is not a superantigen and T, Sag and IM are linked together via organic linkers B; b) x, y and z are integers that typically are selected among 0-10 and represent the number of moieties T, Sag and IM, respetively, in a given conjugate molecule, with the provision that y>0 and also one or both of x and z>0. The superantigen conjugate is preferably a triple fusion protein.Type: ApplicationFiled: December 27, 2004Publication date: October 13, 2005Applicant: ACTIVE BIOTECH ABInventors: Morten Soegaard, Lars Abrahmsen, Peter Lando, Goran Forsberg, Terje Kalland, Mikael Dohlsten
-
Publication number: 20050143800Abstract: In one aspect, an apparatus is provided for securing an electrical stimulation lead in position in a person's brain. The apparatus includes a flexible disc comprising a substantially radial slot adapted to secure the lead in position within the brain after implantation. The slot is adapted to elastically expand as the lead is inserted into the slot and is also adapted to elastically contract on the lead to secure the lead in position within the brain after implantation. The apparatus further includes a ring adapted to seat within a burr hole formed in the person's skull. The ring comprises a channel adapted to receive and secure the flexible disc.Type: ApplicationFiled: December 10, 2004Publication date: June 30, 2005Inventors: Peter Lando, Terry Daglow, John Erickson
-
Publication number: 20040146531Abstract: The present invention relates to a carrier for introduction of substances into cells comprising a modified major capsid protein L1 of human papillomavirus (HPV-L1 protein) devoid of type-specific epitopes causing production of neutralising antibodies. The invention also includes an oligo- or polynucleotide coding for said carrier, vaccines comprising said carrier or said oligo- or polynucleotide, as well as methods of using the carrier or the oligo- or polynucleotide in vaccination against viral, bacterial or parasite infections as well as against development of certain cancers. Especially, infections of human papillomavirus and the development of cancer as a consequence of such infections are recognised.Type: ApplicationFiled: January 20, 2004Publication date: July 29, 2004Applicant: Active Biotech ABInventors: Per Antonsson, Karin Kristensson, Marie Wallen-Ohman, Joakim Dillner, Peter Lando
-
Patent number: 6197299Abstract: A soluble antibody conjugate comprising an antibody linked to a structure which is recognized by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a method for the lysis of target cells, wherein the target cells are contacted with a target cell lysis effective amount of the conjugate. The method of lysis is part of a potent treatment regime for cancer, autoimmunity, parasitic infestations and fungal, viral and bacterial infections. The specification also describes modes such as the synthesis of the conjugate and pharmaceutical compositions and their manufacture.Type: GrantFiled: September 16, 1998Date of Patent: March 6, 2001Assignee: Pharmacia & Upjohn ABInventors: Mikael Dohlsten, Eva Åkerblom, Peter A. Lando, Terje Kalland, Gunnar Hedlund
-
Patent number: 6042837Abstract: Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC), including methods of lysing malignant cells expressing MHC Class II antigens using SDCC, by the administration of staphylococcal enterotoxin to a living body.Type: GrantFiled: February 5, 1996Date of Patent: March 28, 2000Inventors: Terje Kalland, Gunnar Hedlund, Mikael Dohlsten, Peter Lando
-
Patent number: 5858363Abstract: A soluble antibody conjugate comprising an antibody linked to a structure which is recognizable by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a method for the lysis of target cells, wherein the target cells are contacted with a target cell lysis effective amount of the conjugate. The method of lysis is part of a potent treatment regime for cancer, autoimmunity, parasitic infestations and fungal, viral and bacterial infections The specification also describes modes such as the synthesis of the conjugate and pharmaceutical compositions and their manufacture.Type: GrantFiled: June 7, 1995Date of Patent: January 12, 1999Assignee: Pharmacia & Upjohn ABInventors: Mikael Dohlsten, Eva Akerblom, Gunnar Hedlund, Peter A. Lando